Thrombozytopenie: Sind Thrombozytentransfusionen vor Legen eines ZVK verzichtbar?
Hamostaseologie. 2024 Feb;44(1):10. doi: 10.1055/s-0044-1782594. Epub 2024 Feb 28.ABSTRACTDIE TRANSFUSIONSRICHTLINIEN BEZüGLICH DER SCHWELLENWERTE FüR DIE THROMBOZYTENZAHL VOR DEM LEGEN EINES ZENTRALEN VENENKATHETERS (ZVK) ENTHALTEN WIDERSPRüCHLICHE EMPFEHLUNGEN, DA QUALITATIV HOCHWERTIGE UND AUSSAGEKRäFTIGE BELEGE FEHLEN. DER ROUTINEMäßIGE EINSATZ VON ULTRASCHALL HAT DIE BLUTUNGSKOMPLIKATIONEN VERRINGERT. F. L. F. VAN BAARLE UND KOLLEGEN üBERPRüFTEN NUN, WIE DER VERZICHT AUF ENTSPRECHENDE TRANSFUSIONEN DAS BLUTUNGSRISIKO BEEINFLUSST.PMID:38417799 | DOI:10.1055/s-0044-1782594 (Source: Hamostaseologie)
Source: Hamostaseologie - February 28, 2024 Category: Hematology Source Type: research
PAS: Die Rolle von Natriumcitrat bei l ängerer Kaltlagerung von Thrombozyten
Hamostaseologie. 2024 Feb;44(1):12. doi: 10.1055/s-0044-1782595. Epub 2024 Feb 28.ABSTRACTKALT GELAGERTE BLUTPLäTTCHEN FINDEN IN DER BEHANDLUNG VON BLUTUNGEN ZUNEHMEND VERWENDUNG. UNTERSCHIEDE IN DEN HERSTELLUNGSVERFAHREN UND LAGERUNGSLöSUNGEN KöNNEN DIE QUALITäT DER THROMBOZYTEN UND IHRE HALTBARKEIT JEDOCH BEEINFLUSSEN. PAS-E UND PAS-F SIND IN EUROPA UND AUSTRALIEN BZW. IN DEN VEREINIGTEN STAATEN ZUGELASSENE ADDITIVLöSUNGEN (PAS). L. JOHNSON UND KOLLEGEN PRüFTEN NUN, OB LABOR- UND KLINISCHE DATEN INTERNATIONAL üBERTRAGBAR SIND.PMID:38417800 | DOI:10.1055/s-0044-1782595 (Source: Hamostaseologie)
Source: Hamostaseologie - February 28, 2024 Category: Hematology Source Type: research
Clonal Hematopoiesis and Cardiovascular Risk: Atherosclerosis, Thrombosis, and beyond
Hamostaseologie. 2024 Feb;44(1):13-20. doi: 10.1055/a-2219-6410. Epub 2024 Feb 28.ABSTRACTAcquired mutations that lead to clonal hematopoiesis have emerged as a new and potent risk factor for atherosclerotic cardiovascular disease and other cardiovascular conditions. Human sequencing studies and experiments in mouse models provide compelling evidence supporting that this condition, particularly when driven by specific mutated genes, contributes to the development of atherosclerosis by exacerbating inflammatory responses. The insights gained from these studies are paving the way for the development of new personalized preve...
Source: Hamostaseologie - February 28, 2024 Category: Hematology Authors: Benedetta Izzi Jos é J Fuster Source Type: research
The Concept of Thromboinflammation
Hamostaseologie. 2024 Feb;44(1):21-30. doi: 10.1055/a-2178-6491. Epub 2024 Feb 28.ABSTRACTInflammation and thrombosis are intricate and closely interconnected biological processes that are not yet fully understood and lack effective targeted therapeutic approaches. Thrombosis initiated by inflammatory responses, known as immunothrombosis, can confer advantages to the host by constraining the spread of pathogens within the bloodstream. Conversely, platelets and the coagulation cascade can influence inflammatory responses through interactions with immune cells, endothelium, or complement system. These interactions can lead t...
Source: Hamostaseologie - February 28, 2024 Category: Hematology Authors: Waltraud C Schrottmaier Alice Assinger Source Type: research
Pathophysiology of Trauma-Induced Coagulopathy
Hamostaseologie. 2024 Feb;44(1):31-39. doi: 10.1055/a-2215-8936. Epub 2024 Feb 28.ABSTRACTTrauma-induced coagulopathy (TIC) is a complex hemostatic disturbance that can develop early after a major injury. There is no universally accepted definition of TIC. However, TIC primarily refers to the inability to achieve sufficient hemostasis in severely injured trauma patients, resulting in diffuse microvascular and life-threatening bleeding. Endogenous TIC is driven by the combination of hypovolemic shock and substantial tissue injury, resulting in endothelial damage, glycocalyx shedding, upregulated fibrinolysis, fibrinogen dep...
Source: Hamostaseologie - February 28, 2024 Category: Hematology Authors: Herbert Sch öchl Felix C F Schmitt Marc Maegele Source Type: research
100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life
Hamostaseologie. 2024 Feb;44(1):59-73. doi: 10.1055/a-2223-9484. Epub 2024 Feb 28.ABSTRACTOne hundred years ago, in 1924, the first description of a patient with a disease, now known as thrombotic thrombocytopenic purpura (TTP) was published by Dr. Eli Moschcowitz. In honor of this report, this article, written by distinguished specialists in TTP, reviews the increase in scientific knowledge on this disease during the last 100 years. It covers the scientific progress from plasma therapy, the first beneficial treatment for TTP, to the elucidation of the pathophysiology, the discovery of ADAMTS13, the development of assays a...
Source: Hamostaseologie - February 28, 2024 Category: Hematology Authors: Bernhard L ämmle Karen Vanhoorelbeke Johanna A Kremer Hovinga Paul Kn öbl Source Type: research
Petition "Verg ütung für medizinische Leistungen - Verbesserung der Rahmenbedingungen für die ambulante Versorgung", ATMP-QS-Richtlinie Hämophilie und aktueller Stand zur Digitalisierung im Gesundheitswesen: E-Rezept
Hamostaseologie. 2024 Feb;44(1):74-75. doi: 10.1055/a-2177-9429. Epub 2024 Feb 28.NO ABSTRACTPMID:38417805 | DOI:10.1055/a-2177-9429 (Source: Hamostaseologie)
Source: Hamostaseologie - February 28, 2024 Category: Hematology Authors: J ürgen Koscielny G ünther Kappert Christoph Sucker Source Type: research
Venous thromboembolism - was is new in the revised AWMF guideline?
Dtsch Med Wochenschr. 2024 Mar;149(6):274-282. doi: 10.1055/a-2128-0005. Epub 2024 Feb 27.ABSTRACTFor the diagnosis of a lower-extremity deep vein thrombosis (LEDVT), venous duplex ultrasound is the method of first choice. If a qualified ultrasonography is not timely available, D-dimer testing, and limited ultrasound protocols (point-of-care ultrasound, POCUS) can contribute to therapeutic decision-making when clinical probability is low. A DOAC-based treatment regimen is preferable to a vitamin K antagonist for both acute therapy and secondary prophylaxis of venous thromboembolism (VTE). Treatment with DOACs is unproblema...
Source: Hamostaseologie - February 27, 2024 Category: Hematology Authors: Birgit Linnemann Katja Sibylle M ühlberg Robert Klamroth Source Type: research
Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion
Hamostaseologie. 2024 Feb 27. doi: 10.1055/a-2263-5706. Online ahead of print.ABSTRACTPatients with an unexplained mild to moderate bleeding tendency are diagnosed with bleeding disorder of unknown cause (BDUC), a classification reached after ruling out other mild to moderate bleeding disorders (MBD) including von Willebrand disease (VWD), platelet function defects (PFDs), coagulation factor deficiencies (CFDs), and non-hemostatic causes for bleeding. This review outlines our diagnostic approach to BDUC, a diagnosis of exclusion, drawing on current guidelines and insights from the Vienna Bleeding Biobank (VIBB). According ...
Source: Hamostaseologie - February 27, 2024 Category: Hematology Authors: Dino Mehic Johanna Gebhart Ingrid Pabinger Source Type: research
Venous thromboembolism - was is new in the revised AWMF guideline?
Dtsch Med Wochenschr. 2024 Mar;149(6):274-282. doi: 10.1055/a-2128-0005. Epub 2024 Feb 27.ABSTRACTFor the diagnosis of a lower-extremity deep vein thrombosis (LEDVT), venous duplex ultrasound is the method of first choice. If a qualified ultrasonography is not timely available, D-dimer testing, and limited ultrasound protocols (point-of-care ultrasound, POCUS) can contribute to therapeutic decision-making when clinical probability is low. A DOAC-based treatment regimen is preferable to a vitamin K antagonist for both acute therapy and secondary prophylaxis of venous thromboembolism (VTE). Treatment with DOACs is unproblema...
Source: Hamostaseologie - February 27, 2024 Category: Hematology Authors: Birgit Linnemann Katja Sibylle M ühlberg Robert Klamroth Source Type: research
Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion
Hamostaseologie. 2024 Feb 27. doi: 10.1055/a-2263-5706. Online ahead of print.ABSTRACTPatients with an unexplained mild to moderate bleeding tendency are diagnosed with bleeding disorder of unknown cause (BDUC), a classification reached after ruling out other mild to moderate bleeding disorders (MBD) including von Willebrand disease (VWD), platelet function defects (PFDs), coagulation factor deficiencies (CFDs), and non-hemostatic causes for bleeding. This review outlines our diagnostic approach to BDUC, a diagnosis of exclusion, drawing on current guidelines and insights from the Vienna Bleeding Biobank (VIBB). According ...
Source: Hamostaseologie - February 27, 2024 Category: Hematology Authors: Dino Mehic Johanna Gebhart Ingrid Pabinger Source Type: research
VTE Risk Assessment and Prevention in Pregnancy
Hamostaseologie. 2024 Feb 26. doi: 10.1055/a-2238-4681. Online ahead of print.ABSTRACTVenous thromboembolism (VTE) remains the leading cause of maternal mortality in pregnancy and the postpartum period. In addition to the higher pregnancy-associated baseline VTE risk, there are several well-established risk factors that can further increase the risk of VTE. At present, a thorough interrogation of these risk factors remains our only tool for estimating which pregnant people may be at an increased risk of VTE, and thus potentially benefit from thromboprophylaxis. However, an important knowledge gap still exists surrounding t...
Source: Hamostaseologie - February 26, 2024 Category: Hematology Authors: Ellen O'Rourke Rehman Faryal Marc Blondon Saskia Middeldorp Fionnuala N í Áinle Source Type: research
Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment
Hamostaseologie. 2024 Feb 14. doi: 10.1055/a-2232-5480. Online ahead of print.ABSTRACTSplanchnic vein thrombosis (SVT) is a rare type of venous thromboembolism occurring within the splanchnic venous system. Portal vein thrombosis is the most common presentation, while Budd-Chiari syndrome is the least common. Liver cirrhosis and abdominal solid cancer are the main local risk factors for SVT, whereas myeloproliferative neoplasms are the predominant systemic risk factors. Signs and symptoms of SVT are nonspecific and include abdominal pain, gastrointestinal bleeding, and ascites. Asymptomatic SVT is not uncommon, and the maj...
Source: Hamostaseologie - February 14, 2024 Category: Hematology Authors: Scott Custo Emma Tabone Alexia Aquilina Alex Gatt Nicoletta Riva Source Type: research
Inflammation, Sepsis, and the Coagulation System
Hamostaseologie. 2024 Feb 14. doi: 10.1055/a-2202-8544. Online ahead of print.ABSTRACTSepsis has been a major health problem for centuries and it is still the leading cause of hospital deaths. Several studies in the past decades have identified numerous biochemical abnormalities in severe cases, and many of these studies provide evidence of the perturbation of the hemostatic system. This can result in complications, such as disseminated intravascular coagulation that can lead to multiorgan failure. Nevertheless, large clinical studies have demonstrated that the simple approach of inhibiting the coagulation processes by any...
Source: Hamostaseologie - February 14, 2024 Category: Hematology Authors: J ános Kappelmayer Ildik ó Beke Debreceni Zsolt Fejes B éla Nagy Source Type: research
Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment
Hamostaseologie. 2024 Feb 14. doi: 10.1055/a-2232-5480. Online ahead of print.ABSTRACTSplanchnic vein thrombosis (SVT) is a rare type of venous thromboembolism occurring within the splanchnic venous system. Portal vein thrombosis is the most common presentation, while Budd-Chiari syndrome is the least common. Liver cirrhosis and abdominal solid cancer are the main local risk factors for SVT, whereas myeloproliferative neoplasms are the predominant systemic risk factors. Signs and symptoms of SVT are nonspecific and include abdominal pain, gastrointestinal bleeding, and ascites. Asymptomatic SVT is not uncommon, and the maj...
Source: Hamostaseologie - February 14, 2024 Category: Hematology Authors: Scott Custo Emma Tabone Alexia Aquilina Alex Gatt Nicoletta Riva Source Type: research
